



PRIOR AUTHORIZATION REQUEST

Cimzia

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL PA** requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

- | | | | |
|---|---|-----|----|
| 1 | Will the requested medication be used in combination with a biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) used for an inflammatory condition? [Note: Biologic DMARDs include Actemra (IV or SC), Kevzara, Cosentyx, Kineret, Orencia (IV or SC), a rituximab product (for example, Rituxan, Truxima), Cimzia, Enbrel, Humira, an infliximab product (for example, Remicade, Inflectra, Renflexis), Simponi (Aria or SC), Ilumya, Siliq, Stelara (IV or SC), or Taltz and targeted synthetic DMARDs include Xeljanz/XR, Olumiant, Rinvoq, or Otezla.]
[If yes, no further questions.] | Yes | No |
|---|---|-----|----|

If you have any
questions, call:
1-888-258-8250

Version 07.2025

PRIOR AUTHORIZATION REQUEST

2	Is the patient currently receiving the requested medication? [If no, skip to question 7.]	Yes	No
3	Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 7.]	Yes	No
4	Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.]	Yes	No
5	Has the patient been on established therapy for at least 3 months? [If no, skip to question 7.]	Yes	No
6	Has documentation been submitted to confirm that the patient has had a clinically significant response to therapy, as determined by the prescriber? ACTION REQUIRED: Submit supporting documentation? [No further questions.]	Yes	No
7	What is the diagnosis or indication? <input type="checkbox"/> Crohn's disease in an adult (this includes patients with fistulizing Crohn's disease or Crohn's disease of the ileal pouch) (If checked, go to 8) <input type="checkbox"/> Rheumatoid arthritis (If checked, go to 14) <input type="checkbox"/> Psoriatic arthritis (PsA) (If checked, go to 20) <input type="checkbox"/> Ankylosing spondylitis (AS) (If checked, go to 27) <input type="checkbox"/> Non-radiographic axial spondylitis (nr-axSpA) (If checked, go to 33) <input type="checkbox"/> Spondyloarthritis (SpA), other subtypes (for example, undifferentiated arthritis, reactive arthritis [Reiter's disease]) [Note: For ankylosing spondylitis, psoriatic arthritis, or non-radiographic axial spondyloarthritis, refer to the respective criteria] (If checked, go to 40) <input type="checkbox"/> Plaque psoriasis (If checked, go to 46) <input type="checkbox"/> Polyarticular juvenile idiopathic arthritis (pJIA) (If checked, go to 52) <input type="checkbox"/> Other (If checked, no further questions)		
8	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
9	Has documentation been submitted to confirm the patient has had a treatment failure with two other systemic agents for Crohn's disease for at least 3 months or	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.

[Note: Examples of systemic therapies for Crohn's disease include azathioprine, 6-mercaptopurine, methotrexate. A trial of mesalamine does not count as a systemic agent for Crohn's disease.]

[If no, no further questions.]

- | | | | |
|----|--|-----|----|
| 10 | Has documentation been submitted to confirm that the patient has had a treatment failure with the preferred TNF inhibitor, an adalimumab product (Simlandi, Hadlima, Yusimry, or adalimumab-adbm), for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.
[If no, no further questions.] | Yes | No |
| 11 | Has documentation been submitted to confirm that the patient has had a treatment failure with a preferred Ustekinumab product (Yesintek, Pyzchiva, Steqeyma), for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.
[If no, no further questions.] | Yes | No |
| 12 | Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication?
(Dosing: 400mg at weeks 0, 2, 4 and then 400mg every 4 weeks thereafter)
[If yes, no further questions.] | Yes | No |
| 13 | Is the the requested medication being prescribed by or in consultation with a gastroenterologist?
[No further questions.] | Yes | No |
| 14 | Is the patient greater than or equal to 18 years of age?
[If no, no further questions.] | Yes | No |
| 15 | Has documentation been submitted to confirm the patient has tried TWO conventional synthetic disease-modifying antirheumatic drugs (DMARD) for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.

[Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.]
[If no, no further questions.] | Yes | No |
| 16 | Has documentation been submitted to confirm that the patient has had a treatment failure with preferred TNF inhibitors, Enbrel (etanercept) AND an adalimumab product (Hadlima, Yusimry, or adalimumab-adbm) for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.
[If no, no further questions.] | Yes | No |

PRIOR AUTHORIZATION REQUEST

17	Has documentation been submitted to confirm that the patient has had a treatment failure with Xeljanz (tofacitinib) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
18	Is the requested medication being prescribed by, or in consultation with, a rheumatologist? [If no, no further questions.]	Yes	No
19	Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication? (Dosing: 400mg at weeks 0, 2, 4 and then 200mg every 2 weeks thereafter) [No further questions.]	Yes	No
20	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
21	Has documentation been submitted to confirm the patient has tried TWO conventional synthetic disease-modifying antirheumatic drugs (DMARD) for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If no, no further questions.]	Yes	No
22	Has documentation been submitted to confirm that the patient has had a treatment failure with the preferred TNF inhibitors, Enbrel (etanercept) AND an adalimumab product (Simlandi, Hadlima, Yusimry, or adalimumab-adbm) for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
23	Has documentation been submitted to confirm that the patient has had a treatment failure with a preferred Ustekinumab product (Yesintek, Pyzchiva, Steqeyma), for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
24	Has documentation been submitted to confirm that the patient has had a treatment failure with Xeljanz (tofacitinib) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
25	Is the requested medication being prescribed by or in consultation with a	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

rheumatologist or a dermatologist?
[If no, no further questions.]

26	Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication? (Dosing: 400mg at weeks 0, 2, 4 and then 200mg every 2 weeks thereafter) [No further questions.]	Yes	No
27	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
28	Does the patient have a documented diagnosis of active ankylosing spondylitis? [If no, no further questions.]	Yes	No
29	Has documentation been submitted to confirm that the patient has had a treatment failure with the preferred TNF inhibitors, Enbrel (etanercept) AND an adalimumab product (Simlandi, Hadlima, Yusimry, or adalimumab-adbm) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
30	Has documentation been submitted to confirm that the patient has had a treatment failure with Xeljanz (tofacitinib) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
31	Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication? (Dosing: 400mg at weeks 0, 2, 4 and 200mg every 2 weeks or 400mg monthly) [If yes, no further questions.]	Yes	No
32	Is the requested medication being prescribed by, or in consultation with, a rheumatologist? [No further questions.]	Yes	No
33	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
34	Is the requested medication being prescribed by, or in consultation with, a rheumatologist? [If no, no further questions.]	Yes	No
35	Does the patient have an objective sign of inflammation, defined as: a C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory? [If yes, skip to question 37.]	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

36	Does the patient have an objective sign of inflammation, defined as: sacroiliitis reported on magnetic resonance imaging (MRI)? [If no, no further questions.]	Yes	No
37	Has the patient tried and failed prescription strength NSAIDs for at least 4 weeks? [If no, no further questions.]	Yes	No
38	Has documentation been submitted to confirm that the patient has had a treatment failure with preferred TNF inhibitors, Enbrel (etanercept) AND an adalimumab product (Simlandi, Hadlima, Yusimry, or adalimumab-adbm) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
39	Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication? (Dosing: 400mg at weeks 0, 2, 4 and 200mg every 2 weeks or 400mg monthly) [No further questions.]	Yes	No
40	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
41	Does the patient have arthritis primarily in the knees, ankles, elbows, wrists, hands and/or feet? [If no, no further questions.]	Yes	No
42	Has documentation been submitted to confirm the patient has tried TWO conventional synthetic disease-modifying antirheumatic drugs (DMARD) for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If no, no further questions.]	Yes	No
43	Has been submitted to confirm that the patient has had a treatment failure with the preferred TNF inhibitors, Enbrel (etanercept) AND an adalimumab product (Simlandi, Hadlima, Yusimry, or adalimumab-adbm) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
44	Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication? (Dosing: 400mg at weeks 0, 2, 4 and 200mg every 2 weeks or 400mg monthly) [If yes, no further questions.]	Yes	No
45	Is the requested medication being prescribed by, or in consultation with, a	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

rheumatologist?

[No further questions.]

46	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
----	--	-----	----

47	Has documentation been submitted to confirm that the patient has tried at least TWO traditional systemic agents for psoriasis for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.	Yes	No
----	--	-----	----

[Note: Examples of traditional systemic agents for psoriasis include methotrexate (MTX), cyclosporine, acitretin tablets.]

[If no, no further questions.]

48	Has documentation been submitted to confirm that the patient has had a treatment failure with the preferred TNF inhibitors, Enbrel (etanercept) AND an adalimumab product (Simlandi, Hadlima, Yusimry, or adalimumab-adbm) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
----	---	-----	----

49	Has documentation been submitted to confirm that the patient has had a treatment failure with a preferred Ustekinumab product (Yesintek, Pyzchiva, Steqeyma), for at least 3 months or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
----	---	-----	----

50	Is the requested medication being prescribed by or in consultation with a dermatologist? [If no, no further questions.]	Yes	No
----	--	-----	----

51	Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication? (Dosing: 400mg every 2 weeks) [No further questions.]	Yes	No
----	---	-----	----

52	Is the patient 2 years of age or older? [If no, no further questions.]	Yes	No
----	---	-----	----

53	Has documentation been provided to confirm the patient has tried ONE other agent for at least 3 months for pJIA, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.	Yes	No
----	--	-----	----

[Note: Examples of other agents for JIA include but not limited to methotrexate (MTX), sulfasalazine, or leflunomide or examples of contraindications to MTX include pregnancy, breast feeding, alcoholic liver disease, immunodeficiency syndrome, blood dyscrasias]

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025



PRIOR AUTHORIZATION REQUEST

[If no, no further questions.]

- | | | | |
|----|--|-----|----|
| 54 | Has documentation been submitted to confirm that the patient has had a treatment failure with the preferred TNF inhibitors, Enbrel (etanercept) AND an adalimumab product (Simlandi, Hadlima, Yusimry, or adalimumab-adbm) for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.
[If no, no further questions] | Yes | No |
| 55 | Has documentation been submitted to confirm that the patient has had a treatment failure with the preferred IL-6 inhibitor, Actemra, for at least 3 months, or is the patient intolerant or the medication contraindicated? ACTION REQUIRED: Submit supporting documentation.
[If no, no further questions] | Yes | No |
| 56 | Does the patient have aggressive disease, as determined by the prescriber?
[If no, no further questions.] | Yes | No |
| 57 | Is the requested medication being prescribed by or in consultation with a rheumatologist?
[If no, no further questions.] | Yes | No |
| 58 | Does the requested dose exceed the Food and Drug Administration approved label dosing for the indication?
(Dosing: (100mg-400mg) at weeks 0, 2, 4 and then (50-200mg) every other week thereafter) | Yes | No |

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use,

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025